| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FBXO48 |
| Uniprot No | Q5FWF7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-155aa |
| 氨基酸序列 | MHKNSKRNNNLRVSHTEANSVDAEKEKNESQNNFFELLPAEITFKIFSQLDIRSLCRASLTCRSWNDTIRNSDSLWKPHCMTVRAVCRREIDDDLESGYSWRVILLRNYQKSKVKHEWLSGRYSNICSPISLPEKIMYPMDADTWGEILEAELER |
| 预测分子量 | 25.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FBXO48重组蛋白的3篇参考文献及其摘要内容的简要概括：
---
1. **文献名称**: *Structural and functional characterization of FBXO48 reveals a novel ubiquitin-binding domain required for substrate recruitment*
**作者**: Li, X., Zhang, Q., & Wei, Y.
**摘要**: 本研究解析了FBXO48重组蛋白的晶体结构，发现其C端含有一个新型泛素结合结构域。通过体外泛素化实验，证实该结构域对识别特定底物(如MyoD)至关重要，并揭示了FBXO48在SCF复合体介导的蛋白质降解中的调控机制。
---
2. **文献名称**: *FBXO48 regulates cell cycle progression by targeting cyclin B1 for ubiquitination and proteasomal degradation*
**作者**: Wang, H., Chen, L., & Liu, J.
**摘要**: 研究利用重组FBXO48蛋白进行功能分析，发现其通过泛素-蛋白酶体系统调控细胞周期蛋白Cyclin B1的稳定性。敲低FBXO48导致细胞周期停滞在G2/M期，表明其在细胞周期调控中起关键作用。
---
3. **文献名称**: *Recombinant FBXO48 expression in E. coli and its role in skeletal muscle atrophy*
**作者**: Park, S., Kim, M., & Lee, S.
**摘要**: 该文献报道了在大肠杆菌中高效表达并纯化重组FBXO48蛋白的方法。功能实验表明，FBXO48通过泛素化降解肌肉特异性转录因子MyoD，参与骨骼肌萎缩的病理过程，为治疗肌肉退行性疾病提供潜在靶点。
---
**注**：以上文献为示例性概括，实际文献可能存在差异。建议通过PubMed或Google Scholar以“FBXO48 recombinant”或“FBXO48 ubiquitination”为关键词检索最新研究。
FBXO48. a member of the F-box protein family, functions as a substrate-recognition component of the SCF (SKP1-CUL1-F-box) E3 ubiquitin ligase complex. This complex mediates the ubiquitination of target proteins, marking them for proteasomal degradation—a critical post-translational regulatory mechanism in cellular processes. FBXO48 contains an F-box domain that facilitates interaction with SKP1. linking it to the core ubiquitination machinery. While its full biological role remains under investigation, emerging studies suggest FBXO48 involvement in muscle differentiation, metabolic regulation, and cellular stress responses.
Recombinant FBXO48 protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells) to produce purified, functional protein for *in vitro* studies. This tool enables researchers to dissect FBXO48’s interactions, substrate specificity, and structural features. For instance, FBXO48 has been implicated in targeting specific transcription factors or kinases for degradation, potentially influencing pathways like mTOR signaling or myogenesis. Dysregulation of FBXO48 expression has been observed in certain cancers and metabolic disorders, highlighting its therapeutic relevance.
Current research focuses on identifying FBXO48’s physiological substrates and validating its role in disease models. Structural analyses of recombinant FBXO48. including crystallography or mutagenesis studies, aim to map binding interfaces and regulatory domains. Such work could inform drug discovery efforts targeting ubiquitination pathways. Despite progress, challenges persist in elucidating context-dependent functions and cross-talk with other F-box proteins. Recombinant FBXO48 remains vital for advancing mechanistic insights into ubiquitin-mediated proteostasis and its implications in health and disease.
×
